Watch Recce Pharmaceuticals Secures Australian Patent for Anti-Infectives

3 min read | November 27, 2024 11:12 AM AEDT | By Team Kalkine Media

Google News:

Watch Recce Pharmaceuticals Secures Australian Patent for Anti-Infectives — Image source: shutterstock

Recent News

ASX Closes Higher as Broad Market Strength Returns

Perseus Mining’s Buyback Move Sparks Fresh Market Interest

Ingenia Communities Gains Attention After Strong Update

Gold and Rare Strength Lift ASX Momentum Again

Make Kalkine Media
My Trusted Source

Highlights

Recce Pharmaceuticals gains Australian patent protection for key anti-infective assets.

Patent extends coverage of RECCE® 327 and RECCE® 529 until 2037.

Advances intellectual property across major markets, supporting innovative therapies.

Recce Pharmaceuticals (ASX:RCE) has achieved a significant milestone with the Australian Patent Office granting approval for Patent Family 3. This patent secures protection for the company’s synthetic anti-infective technologies, specifically RECCE® 327 (R327) and RECCE® 529 (R529), extending their coverage until 2037. This marks a crucial step in Recce’s commitment to developing innovative solutions targeting bacterial and viral infections.

Comprehensive Intellectual Property Coverage

The newly granted Australian patent strengthens Recce’s global patent portfolio, completing its intellectual property coverage across critical regions, including the United States, Europe, China, Japan, and others. This achievement enhances the company’s position as a key player in combating drug-resistant infections worldwide. The patent protects the manufacturing process for RECCE® anti-infectives and their application in treating infections through multiple methods of administration, such as oral, injectable, inhalable, and transdermal routes.

Focus on Antibiotic-Resistant and Viral Threats

Recce’s pipeline addresses urgent healthcare challenges, including antibiotic-resistant superbugs. Its flagship products, R327 and R435, are focused on bacterial infections, while R529 targets viral threats. The company’s innovative approach has earned recognition from global authorities, including the World Health Organization (WHO).

Regulatory Designations and Clinical Advancements

In addition to its patent achievements, Recce’s R327 has received key designations from the U.S. Food and Drug Administration (FDA), which include Qualified Infectious Disease Product (QIDP) status. This designation provides market exclusivity for a decade upon approval, further bolstering Recce’s ability to bring effective therapies to market.

Proprietary Manufacturing and Clinical Progress

Recce’s proprietary manufacturing capabilities are integral to its clinical development programs. These capabilities ensure the efficient production of its anti-infective solutions, supporting ongoing clinical trials aimed at addressing critical unmet medical needs. With a strong pipeline and a solid intellectual property foundation, Recce Pharmaceuticals (ASX:RCE) continues to advance innovative treatments for global bacterial and viral threats.

This development underscores the company’s role in revolutionizing the treatment of drug-resistant infections while strengthening its position in the global pharmaceutical landscape.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.